SHANGHAI, China, June 30, 2021 - Ping An-Shionogi Co., Ltd. (Head Office: Shanghai, China; Chairman and CEO: Tatsumori Yoshida, hereafter "Ping An-Shionogi") and Ping An Healthcare and Technology Co., Ltd. (Head Office: Shanghai, China; Chairman and CEO: Fang Weihao, hereafter "Ping An-Health") have entered into a new business collaboration for Real World Data (RWD) collection and analysis research for patients with metabolic diseases.
In this research, Ping An-Shionogi will utilize the online healthcare platform "Ping An Good Doctor" owned by Ping An-Health and the products sold by Ping An-Shionogi. When the drug is prescribed to a patient, Ping An-Shionogi can obtain the informed consent from the patients to participate in this research and provide a wearable device and smartphone app. The wearable device and the app can provide RWD such as the patient's medication log, sleep/activity, mental state, cognitive function, and so on. Since the RWD is visualized on the app in a user-friendly style for the patient to easily understand, participants can check it by themselves. Ping An-Health will develop the original app for this research, operate the app to collect data from the patients and securely manage the healthcare data.
Through this research, Ping An-Shionogi can contribute to improving the medication adherence of patients, early detection and treatment of comorbidities, and provision of excellent healthcare services. Ping An-Health is also expected to contribute to improving the QOL of users of the company's online healthcare platform. In addition, this research will help to accelerate data-driven drug discovery, which is an important part of the research and development concept of Ping An-Shionogi. By building a digital platform that enables the collection and analysis of high-quality RWD, starting with this study in metabolic disease and the moving into CNS conditions such as dementia and depression, which is one of Shionogi’s priority areas, and continuing clinical research activity leveraging the AI technology of the Ping An Group※1, Ping An-Shionogi will work to create new drugs and services that make full use of healthcare data.
Ping An-Shionogi seeks to address the issues facing patients and society NOT as a conventional pharmaceutical company that provides only ethical drugs, but as “a HaaS※2 company” that provides comprehensive healthcare services and continuously offers new value to society. Under a long-term and strong strategic partnership with the Ping An Group, Ping An-Shionogi will continue to work on the realization of HaaS by synergistic cooperation combining our different strengths, science and digital technology.
※1 Ping An Group; Subsidiaries and affiliates of Ping An Insurance (Group) Company of China Ltd.
※2 HaaS; Healthcare as a Service: Provide a range of healthcare services in line with customer needs, rather than only supplying pharmaceuticals.
About Outline of RWD research
This study will enroll 1,000 patients with metabolic diseases. The patients will be provided with a wearable device and a compatible app to monitor various parameters in daily life. By analyzing the data obtained, including follow up the patients, key correlations can be identified to create concept for new drugs and healthcare services, with the monitoring results such as linkages between adherence and QOL changes. The collected data will be anonymized, processed and strictly managed, and will not be taken out of China.
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
For Further Information, Contact:
Ping An-Shionogi Website Inquiry Form : firstname.lastname@example.org